<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>28461150</identifier>
<setSpec>1885-5857</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Morillas Bueno, Miren</dc:author>
<dc:author>Larman, Mariano</dc:author>
<dc:author>Ruiz Guerrero, Luis</dc:author>
<dc:author>Rubio Patón, Ramón</dc:author>
<dc:author>de la Morena, Gonzalo</dc:author>
<dc:author>Arnold, Román</dc:author>
<dc:author>Roa, Jessica</dc:author>
<dc:author>Ruisánchez, Cristina</dc:author>
<dc:author>Sánchez Gila, Joaquín</dc:author>
<dc:author>Tizón, Helena</dc:author>
<dc:author>Pan, Manuel</dc:author>
<dc:author>Pinar, Eduardo</dc:author>
<dc:author>García Camarero, Tamara</dc:author>
<dc:author>Echegaray, Kattalin</dc:author>
<dc:author>Sabate, Manel</dc:author>
<dc:author>Gutiérrez, Hipólito</dc:author>
<dc:author>Oyonarte, José M</dc:author>
<dc:author>Díaz, José F</dc:author>
<dc:author>Ble, Mireia</dc:author>
<dc:author>de la Torre Hernández, José M</dc:author>
<dc:author>Brugaletta, Salvatore</dc:author>
<dc:author>Rumoroso, José R</dc:author>
<dc:author>Ojeda, Soledad</dc:author>
<dc:author>Cascón, José D</dc:author>
<dc:description xml:lang="en">INTRODUCTION AND OBJECTIVES Bioresorbable vascular scaffolds (BVS) have the potential to restore vasomotion but the clinical implications are unknown. We sought to evaluate angina and ischemia in the long-term in patients treated with BVS and metallic drug-eluting stents (mDES). METHODS Multicenter study including patients with 24 ± 6 months of uneventful follow-up, in which stress echocardiography was performed and functional status was assessed by the Seattle Angina Questionnaire (SAQ). The primary endpoint was a positive result in stress echocardiography. RESULTS The study included 102 patients treated with BVS and 106 with mDES. There were no differences in the patients' baseline characteristics. Recurrent angina was found in 18 patients (17.6%) in the BVS group vs 25 (23.5%) in the mDES group (P = .37), but SAQ results were significantly better in the BVS group (angina frequency 96.0 ± 8.0 vs 89.2 ± 29.7; P = .02). Stress echocardiography was positive in 11/92 (11.9%) of BVS patients vs 9/96 (9.4%) of mDES patients in the (P = .71) and angina was induced in 2/102 (1.9%) vs 7/106 (6.6%) (P = .18), respectively, but exercise performance was better in the BVS group even in those with positive tests (exercise duration 9.0 ± 2.0minutes vs 7.7 ± 1.8minutes; P = .02). A propensity score matching analysis yielded similar results. CONCLUSIONS The primary endpoint was similar in both groups. In addition, recurrent angina was similar in patients with BVS and mDES. The better functional status, assessed by means of SAQ and exercise performance, detected in patients receiving BVS should be confirmed in further studies.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Ecografía de estrés</dc:subject>
<dc:subject>Stress echocardiography</dc:subject>
<dc:subject>Armazón bioabsorbible</dc:subject>
<dc:subject>Ischemia</dc:subject>
<dc:subject>Drug-eluting stent</dc:subject>
<dc:subject>Stent farmacoactivo</dc:subject>
<dc:subject>Isquemia</dc:subject>
<dc:subject>Angina</dc:subject>
<dc:subject>Bioresorbable scaffold</dc:subject>
<dc:date>2017 Apr 29 </dc:date>
<dc:title xml:lang="en">Angina and Ischemia at 2 Years With Bioresorbable Vascular Scaffolds and Metallic Drug-eluting Stents. ESTROFA Ischemia BVS-mDES Study.</dc:title>
<dc:publisher>Revista espanola de cardiologia (English ed.)</dc:publisher>
</metadata>
</record>
</pubmed-document>
